Registration is open until May 8th. 3rd Annual Global C.diff. Awareness 2K Walks.
The USA events will take place on Saturday, May 18, 2019 from 8 a.m. – 12 p.m.
Dr. Martha Cloakie, PhD will be leading the walk in Leicester, U.K. on Friday, May 17, 2019.
All registered awareness walkers will receive t-shirts, giveaways, and educational material while introducing the communities to the resources available. C.diff. infections are one of the leading healthcare-associated infections facing local communities.
Registration is $20.00 per walker and children 10 years of age and under walk free. https://cdifffoundation.org/3rdannualwalk/
Proceeds from the events will benefit the C Diff Foundation’s mission educating and advocating for C.difficile infection prevention, treatments, clinical trials, environmental safety, sepsis, and antibiotic awareness worldwide.
According to the Centers for Disease Control and Prevention (CDC), a Clostridioides difficile infection (C.difficile), (formally known as Clostridium difficile) “has become the most common microbial cause of healthcare-associated infections in U.S. hospitals and costs up to $4.8 billion each year in excess health care costs for acute care facilities alone.”
Statistics provided by the CDC suggest that C. difficile cause nearly 500,000 infections in patients in the U.S. annually. In one study noted by the CDC, among infected patients, nearly 29,000 died within 30 days of being diagnosed, and more than half of those deaths (15,000) were directly attributable to a C. difficile infection.
We sincerely thank Vedanta Biosciences, Inc. for being the Diamond Sponsor of the 3rd Annual Global C.diff. Awareness 2K Walks. Vedanta Biosciences, Inc. is dedicated to finding treatments for patients with serious infections and immune diseases. Vedanta develops medicines made of consortia of bacterial strains which are selected to effect robust and durable changes in a patient’s gut microbiota. In contrast to fecal transplants or administration of fecal fractions, Vedanta’s medicines are pure, uniform compositions of bacteria manufactured from clonal cell banks, bypassing the need to rely on direct sourcing of fecal donor material of inconsistent composition. Vedanta is currently enrolling patients with recurrent C. difficile infections (CDI) in its CONSORTIUM study to evaluate VE303, an investigational treatment for CDI.
Our gratitude to all of the sponsors for their support and partnering with the C Diff Foundation in raising C. diff. awareness worldwide:
Silver Sponsor: CutisPharma
Bronze Sponsor: Finch Therapeutics
If you have any questions, please contact one of our staff members at
(727) – 205 – 3922 or e-mail: email@example.com
We look forward to walking with you on May 18th!
Follow Us On Twitter: #CdiffWalks2019